EC looks for support on central nanotech regulatory drafting framework
This article was originally published in Clinica
Executive Summary
The European Commission is calling for responses from interested stakeholders, including the medical technology industry, to the opinion on nanotechnologies that has just been adopted by independent experts at its scientific committee on emerging and newly identified health risks (SCENIHR). Speaking at a conference on nanotechnology held by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on October 27, Didier Bouis, the person in charge of looking into the regulation of all areas of nanotechnology within the European Commission's Directorate General for Enterprise and Industry, explained that the EU is still at very preliminary stages of considering how nanotechnology products, including nanomedicines, should be regulated.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.